These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 30062699)

  • 1. TIMI-AF score and cardiovascular events in vitamin K antagonists-naïve outpatients with atrial fibrillation.
    Pérez Cabeza AI; Bravo Marques R; Chinchurreta Capote PA; Ruiz Mateas F; Fanola CL; Rosas Cervantes G; González Correa JA; Valle Alberca A; Mesa Prado F; López Tejero S; Ruff CT
    Clin Cardiol; 2018 Sep; 41(9):1252-1258. PubMed ID: 30062699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct oral anticoagulants versus vitamin K antagonists in real-world patients with nonvalvular atrial fibrillation. The FANTASIIA study.
    Anguita Sánchez M; Bertomeu Martínez V; Ruiz Ortiz M; Cequier Fillat Á; Roldán Rabadán I; Muñiz García J; Badimón Maestro L; Esteve Pastor MA; Marín Ortuño F;
    Rev Esp Cardiol (Engl Ed); 2020 Jan; 73(1):14-20. PubMed ID: 31160265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of long-term net clinical outcomes using the TIMI-AF score: Comparison with CHA
    Rivera-Caravaca JM; Roldán V; Esteve-Pastor MA; Valdés M; Vicente V; Marín F; Lip GYH
    Am Heart J; 2018 Mar; 197():27-34. PubMed ID: 29447781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study.
    Russo V; Attena E; Di Maio M; Mazzone C; Carbone A; Parisi V; Rago A; D'Onofrio A; Golino P; Nigro G
    J Thromb Thrombolysis; 2020 Jan; 49(1):42-53. PubMed ID: 31385163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.
    Russo V; Carbone A; Attena E; Rago A; Mazzone C; Proietti R; Parisi V; Scotti A; Nigro G; Golino P; D'Onofrio A
    Clin Ther; 2019 Dec; 41(12):2549-2557. PubMed ID: 31735436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events.
    Lemesle G; Ducrocq G; Elbez Y; Van Belle E; Goto S; Cannon CP; Bauters C; Bhatt DL; Steg PG;
    Clin Cardiol; 2017 Oct; 40(10):932-939. PubMed ID: 28692742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation.
    Gallego P; Roldán V; Torregrosa JM; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
    Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):312-8. PubMed ID: 22319005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct Anticoagulants Versus Vitamin K Antagonists in Patients Aged 80 Years or Older With Atrial Fibrillation in a "Real-world" Nationwide Registry: Insights From the FANTASIIA Study.
    Ortiz MR; Muñiz J; Esteve-Pastor MA; Marín F; Roldán I; Cequier A; Martínez-Sellés M; Saldivar HG; Bertomeu V; Anguita M
    J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):316-323. PubMed ID: 32228180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of oral anticoagulation in patients with atrial fibrillation at very low thromboembolic risk.
    Verbrugge FH; Martin AC; Siegal D; Pieper K; Illingworth L; Camm AJ; Fox KAA
    Heart; 2020 Jun; 106(11):845-851. PubMed ID: 31806700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A population database study of outcomes associated with vitamin K antagonists in atrial fibrillation before DOAC.
    Blin P; Dureau-Pournin C; Lassalle R; Abouelfath A; Droz-Perroteau C; Moore N
    Br J Clin Pharmacol; 2016 Mar; 81(3):569-78. PubMed ID: 26493768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Body Mass Index With Clinical Outcomes in Patients With Atrial Fibrillation: A Report From the FANTASIIA Registry.
    Bertomeu-Gonzalez V; Moreno-Arribas J; Esteve-Pastor MA; Roldán-Rabadán I; Muñiz J; Raña-Míguez P; Ruiz-Ortiz M; Cequier Á; Bertomeu-Martínez V; Badimón L; Anguita M; Lip GYH; Marín F;
    J Am Heart Assoc; 2020 Jan; 9(1):e013789. PubMed ID: 31870235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project.
    Philippart R; Brunet-Bernard A; Clementy N; Bourguignon T; Mirza A; Angoulvant D; Babuty D; Lip GY; Fauchier L
    Thromb Haemost; 2016 May; 115(5):1056-63. PubMed ID: 26843425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do CHA2 DS2 VASc and HAS-BLED scores influence 'real-world' anticoagulation management in atrial fibrillation? 1556 patient registry from the reference cardiology centre.
    Lopatowska P; Tomaszuk-Kazberuk A; Mlodawska E; Bachorzewska-Gajewska H; Malyszko J; Dobrzycki S; Musial WJ
    Pharmacoepidemiol Drug Saf; 2015 Dec; 24(12):1297-303. PubMed ID: 26419506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation.
    Gallego P; Roldan V; Marín F; Romera M; Valdés M; Vicente V; Lip GY
    Thromb Haemost; 2013 Dec; 110(6):1189-98. PubMed ID: 24096615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
    Lee SI; Sayers M; Lip GY; Lane DA
    Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants.
    Pastori D; Lip GYH; Farcomeni A; Del Sole F; Sciacqua A; Perticone F; Marcucci R; Grifoni E; Pignatelli P; Violi F;
    Int J Cardiol; 2018 Aug; 264():58-63. PubMed ID: 29776574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of the SAMe-TT₂R₂ score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation.
    Lip GYH; Haguenoer K; Saint-Etienne C; Fauchier L
    Chest; 2014 Sep; 146(3):719-726. PubMed ID: 24722973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do physicians correctly calculate thromboembolic risk scores? A comparison of concordance between manual and computer-based calculation of CHADS2 and CHA2 DS2 -VASc scores.
    Esteve-Pastor MA; Marín F; Bertomeu-Martinez V; Roldán-Rabadán I; Cequier-Fillat Á; Badimon L; Muñiz-García J; Valdés M; Anguita-Sánchez M;
    Intern Med J; 2016 May; 46(5):583-9. PubMed ID: 26929032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of CHA
    Hjelholt TJ; Johnsen SP; Brynningsen PK; Pedersen AB
    J Am Geriatr Soc; 2020 Aug; 68(8):1698-1705. PubMed ID: 32294240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.